Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company is engaged in developing, manufacturing, and marketing of complex injectables and has presence in over 60 countries as of March 31, 2020, including the United States, India, Canada, Australia, Europe, etc. Some of the company’s customers include leading pharmaceutical companies like Sagent Pharmaceuticals, Apotex Inc. Athenex Pharmaceutical Division, Fresenius Kabi USA, etc.
Backed by global pharma major Fosun Pharma, the company could become the first Indian company backed by Chinese promoter to list on Dalal Street.
The size of the public offering is expected to be around Rs. 6000 crores, which includes the issuance of fresh equity shares of up to Rs. 1250 crores as well as Offer for Sale of 3.49 crore equity shares from promoters. You can read the IPO Prospectus for detailed information.
|Issue Period||November 9, 2020 - November 11, 2020|
|Price Range||1490 - 1500|
|Minimum Bid Quantity||10 and in multiples thereof|
|Finalisation of Allotment||November 17, 2020|
|Initiation of Refunds||November 18, 2020|
|Credit of Shares||November 19, 2020|
|Listing||November 20, 2020|
|Mandate end date||November 29, 2020|
How do I apply for the Gland Pharma IPO?
You can apply for the Gland Pharma IPO using any supported UPI app by following two steps:
- Enter your bid on Console
- Accept UPI mandate on your phone
On acceptance of the mandate, the bid amount will get blocked in your bank account. Click here to learn more.